Patient characteristics, description of treatments, and clinical outcomes
| ID . | Patient . | Cell treatment . | Response (duration in months)* . | |||
|---|---|---|---|---|---|---|
| Age/sex . | Evaluable disease sites . | TCR antigen . | Infusion no. (×109) . | Vaccine type . | ||
| 4 | 52/M | Li, Ly | MART-1 | 1.0 | p-27L | PR (34) |
| 5 | 50/M | Sq | MART-1 | 13 | p-27L | NR |
| 8 | 37/M | Lu, Ly | MART-1 | 6.1 | p-27L | NR |
| 9 | 53/M | Ad, Ly, Sq | MART-1 | 4.2 | p-27L | MR |
| 10 | 45/M | Ad, Ki, Ly, Sq | MART-1 | 8.6 | p-27L | NR |
| 11 | 45/M | Lu, Ly, Pa | MART-1 | 6.3 | p-27L | NR |
| 14 | 30/M | Ly | MART-1 | 86 | p-27L | CR (52+) |
| 17 | 20/F | Im, Lu, Ly, Sq | MART-1 | 23 | p-27L | NR |
| 19† | 52/M | Ly, Rp | MART-1 | 40 | p-27L | NR |
| 20† | 48/M | Lu | MART-1 | 37 | p-27L | NR |
| A | 42/F | Ly, Sq | gp100 | 24 | p-210M | NR |
| B | 44/F | Cu | gp100 | 3.8 | p-210M | NR |
| D | 52/F | Lu, Ly | gp100 | 11 | rFP-210M‡ | NR |
| E | 61/M | Ly | gp100 | 48 | rFP-210M‡ | NR |
| F | 27/M | Ad, Li, Lu, Rp | gp100 | 22 | rFP-210M‡ | NR |
| G | 44/M | Ad | gp100 | 40 | rFP-210M‡ | NR |
| H | 52/F | Lu, Ly, Sq | gp100 | 34 | rFP-210M‡ | NR |
| I | 46/F | Ip, Li, Ly | gp100 | 32 | rFP-210M‡ | NR |
| ID . | Patient . | Cell treatment . | Response (duration in months)* . | |||
|---|---|---|---|---|---|---|
| Age/sex . | Evaluable disease sites . | TCR antigen . | Infusion no. (×109) . | Vaccine type . | ||
| 4 | 52/M | Li, Ly | MART-1 | 1.0 | p-27L | PR (34) |
| 5 | 50/M | Sq | MART-1 | 13 | p-27L | NR |
| 8 | 37/M | Lu, Ly | MART-1 | 6.1 | p-27L | NR |
| 9 | 53/M | Ad, Ly, Sq | MART-1 | 4.2 | p-27L | MR |
| 10 | 45/M | Ad, Ki, Ly, Sq | MART-1 | 8.6 | p-27L | NR |
| 11 | 45/M | Lu, Ly, Pa | MART-1 | 6.3 | p-27L | NR |
| 14 | 30/M | Ly | MART-1 | 86 | p-27L | CR (52+) |
| 17 | 20/F | Im, Lu, Ly, Sq | MART-1 | 23 | p-27L | NR |
| 19† | 52/M | Ly, Rp | MART-1 | 40 | p-27L | NR |
| 20† | 48/M | Lu | MART-1 | 37 | p-27L | NR |
| A | 42/F | Ly, Sq | gp100 | 24 | p-210M | NR |
| B | 44/F | Cu | gp100 | 3.8 | p-210M | NR |
| D | 52/F | Lu, Ly | gp100 | 11 | rFP-210M‡ | NR |
| E | 61/M | Ly | gp100 | 48 | rFP-210M‡ | NR |
| F | 27/M | Ad, Li, Lu, Rp | gp100 | 22 | rFP-210M‡ | NR |
| G | 44/M | Ad | gp100 | 40 | rFP-210M‡ | NR |
| H | 52/F | Lu, Ly, Sq | gp100 | 34 | rFP-210M‡ | NR |
| I | 46/F | Ip, Li, Ly | gp100 | 32 | rFP-210M‡ | NR |
See Figure 1 for protocol description.
Ad indicates adrenal; CR, complete response; Cu, cutaneous; Im, intramuscular; Ip, intraperitoneal; Ki, kidney; Li, liver; Lu, lung; Ly, lymphatic; MR, mixed or minor response; NR, no response; p-210M, anchor-modified gp100 peptide vaccine; p-27L, anchor-modified MART-1 peptide vaccine; Pa, pancreas; PR, partial response; rFP-210M, recombinant fowlpox anchor-modified gp100 vaccine; Rp, retroperitoneal; and Sq, subcutaneous.
Based on Response Evaluation Criteria in Solid Tumors classification.26
These patients received CD8-enriched cells.
Vaccine, in combination with high-dose IL-2, was readministered at 1 month after cell infusion.